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Background: Non alcoholic fatty liver disease (NAFLD) is associated with increased risk of type 2 diabetes and
chronic liver disease but identifying patients who have NAFLD without resorting to expensive imaging tests is
challenging. In order to help identify people for imaging investigation of the liver who are at high risk of NAFLD,
our aim was to: a) identify easily measured risk factors at baseline that were independently associated with incident
fatty liver at follow up, and then b) to test the diagnostic performance of thresholds of these factors at baseline, to
predict or to exclude incident fatty liver at follow up.
Methods: 2589 people with absence of fatty liver on ultrasound examination at baseline were re-examined after a
mean of 4.4 years in a Korean occupational cohort study. Multi-variable logistic regression analyses were used to
identify baseline factors that were independently associated with incident fatty liver at follow up. The diagnostic
performance of thresholds of these baseline factors to identify people with incident fatty liver at follow-up was
assessed using receiver operating characteristic (ROC) curves.
Results: 430 incident cases of fatty liver were identified. Several factors were independently associated with
incident fatty liver: increased triglyceride (per mmol/l increase) OR 1.378 [95%CIs 1.179, 1.611], p < 0.0001; glucose
(per mmol/l increase) OR 1.215 [95%CIs 1.042, 1.416], p = 0.013; waist (per cm increase) OR 1.078 [95%CIs 1.057,
1.099], p < 0.001; ALT (per IU/L increase) OR 1.009 [95%CIs 1.002, 1.017], p = 0.016; and platelets (per 1x109/L
increase) OR 1.004 [1.001, 1.006], p = 0.001; were each independently associated with incident fatty liver. Binary
thresholds of the five factors were applied and the area under the ROC curve for incident fatty liver was 0.75 (95%
CI 0.72–0.78) for the combination of all five factors above these thresholds.
Conclusion: Simple risk factors that overlap considerably with risk factors for type 2 diabetes allow identification of
people at high risk of incident fatty liver at who use of hepatic imaging could be targeted.
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Prevalence estimates for non alcoholic fatty liver disease
(NAFLD) range from 17% to 33% in general populations
in Western countries [1,2] and it is predicted that
NAFLD will soon become the most important contribu-
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reproduction in any medium, provided the oralso associated with type 2 diabetes, cardiovascular dis-
ease [4,5] and insulin resistance [6] in muscle, adipose
and liver [7].
Patients with possible NAFLD are treated by a range
of specialists [8] who have to decide which patients are
at sufficiently high risk to investigate further to make
the diagnosis. Readily available single anthropometric
tests or blood tests lack sufficient sensitivity or specifi-
city to identify patients with NAFLD. For example, a
body mass index (BMI) ≥25 kg/m2 as a measure of over-
weight or obesity, is not specific for NAFLD, because
not all overweight or obese people have fatty liver; and
an alanine transaminase (ALT) value > 31U/l in men andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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test for NAFLD [9]. It is therefore difficult to select
appropriate patients for expensive radiological diagnostic
imaging tests such as ultrasound, because single tests
lack sufficient sensitivity and specificity to identify high
risk patients. Although other more sensitive techniques
than ultrasound are available for detecting liver fat, e.g.
proton magnetic resonance spectroscopy (MRS) [10,11],
MRS is an expensive diagnostic test and is also imperfect
at identifying the extent or severity of NAFLD. Conse-
quently, ultrasound is usually the preferred initial radiolo-
gical test employed by most clinicians to establish the
presence of moderate or large amounts of liver fat.
There is increasing interest in developing algorithms
or risk scores for identifying liver fat, because accumula-
tion of liver fat or some component of fat metabolism is
the prerequisite for progression of NAFLD to steatohe-
patitis and fibrosis [12]. Several investigators have under-
taken cross sectional studies examining relationships
between risk factors and prevalent fatty liver [13-17], but
the ability of these risk factors, or algorithms, to predict
incident fatty liver in a prospective study is uncertain.
Recently, in a cross sectional study of people with and
without diabetes, and people recruited from gastroenter-
ology clinics, Kotronen et al. developed a NAFLD liver
fat score based on serum insulin, aspartate transaminase
(AST), ALT concentrations, presence or absence of
metabolic syndrome and type 2 diabetes. These investi-
gators validated the fat score against the presence and
quantity of hepatic fat as assessed by MRS [18]. In this
study, the optimum liver fat score cut-point had 86%
sensitivity and 71% specific for predicting NAFLD [18].
Although these data suggest an excellent performance of
the liver fat score, an accompanying editorial suggested
the score was ‘not ready for prime time’[19], not least
because of the cross sectional study design and the lim-
ited potential applicability of these findings to generalApparently healthy subjects screened by li
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Figure 1 Flow chart summarizing the selection of study participants.populations as some participants were recruited from
hospital clinics.
We have undertaken a cohort study of people who
were shown to be free from hepatic steatosis on ultra-
sound examination at baseline, and who had a further
ultrasound examination at follow up an average of
4.4 years later. We used these data to identify individuals
who had developed new (incident) fatty liver during the
follow up period. Since there are no guidelines to help
identify which patients should undergo ultrasound test-
ing to diagnose fatty liver, the aim of our study was to:
a) identify easily measured risk factors at baseline that
were independently associated with incident fatty liver at
follow up, and then b) to test the diagnostic performance
of thresholds of these factors to predict or to exclude
incident fatty liver at follow up.
Methods
Electronic medical records were used to identify 4463
participants from a cohort of Korean employees who
had had an occupational health check in 2003–2005 that
included collection of data on anthropometry and liver
ultrasound. Information on smoking history (never, cur-
rent, or past) and whether individuals participated in
any regular exercise was obtained by questionnaire. A
follow up examination was performed in 2008 and 2009 at
Kangbuk Samsung Hospital in Seoul, Korea and people
without fatty liver at baseline were only included if they
had a further ultrasound at follow-up (Figure 1). The insti-
tutional review board of Kangbuk Samsung Hospital
approved this study.
We excluded participants with positive serologic mar-
ker for hepatitis B (n = 188) or hepatitis C virus (n = 13)
and alcohol consumption in excess of 20 g/day (n = 531).
Regular exercise and smoking status were assessed by a
physician administered questionnaire. Individuals were
asked if they had participated in any regular exercise atver ultrasound in 2003-2005 (n=4463)
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589)
t f ll i 2008 2009 ( 430)o ow up n - n=
Sung et al. BMC Gastroenterology 2012, 12:84 Page 3 of 9
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never, ex and current smoker. Data were specifically
requested from the central source on those individuals
who had a complete data-set for all these measurements.
Plasma and serum were collected after at least 12 h of
fasting. Glucose was measured using the hexokinase
method (Advia 1650 Autoanalyzer; Bayer Diagnostics,
Leverkusen, Germany). Insulin was measured with an
immunoradiometric assay (Biosource, Nivelle, Belgium)
(intra- and interassay coefficient of variation of 2.1–4.5%
and 4.7–12.2%, respectively). An enzymatic calorimetric
test was used to measure total cholesterol and trigly-
ceride concentrations. High density lipoprotein choles-
terol (HDLc) concentration was measured by the
selective inhibition method and a homogeneous enzy-
matic calorimetric test was used to measure low density
lipoprotein cholesterol (LDLc) concentration (Advia
1650 Autoanalyzer). High-sensitivity C-reactive protein
(hs-CRP) was analysed by performing particle-enhanced
immunonephelomety using the BN System (Dade
Behring, Marburg, Germany). HOMA-IR (Homeostasis
Model Assessment of Insulin Resistance) was calculated
as a measure of insulin resistance [20]. Abdominal ultra-
sonography (Logic Q700 MR; GE, Milwaukee,WI, USA)
was performed in all subjects by experienced clinical
radiologists and fatty liver was diagnosed based on
known standard criteria, including hepatorenal echo con-
trast, liver brightness, and vascular blurring, using a
3.5 MHz probe [21].Risk prediction modeling for fatty liver comparing
established and population-specific newly optimized
thresholds
All the observations including ultrasound and blood
tests that are included in the analyses were undertaken
at base-line and data from a further ultrasound per-
formed at follow up was available for people without
fatty liver at baseline. Established thresholds for meta-
bolic risk factors (waist, glucose and triglyceride) were
identified according to the Joint Interim Statement 2009
criteria for the metabolic syndrome (MetS) [22].
For ALT, we used sex specific cut-offs for normal liver
function that have been shown to exclude NAFLD [9].
For platelet number, we used the lower limit of normal
for Kangbuk Samsung Hospital, Korea as the cut point
(158 × 109/l).
Additionally, we also identified new population-
specific optimized thresholds of each variable that
showed the highest accuracy (based on the area under
receiver operating curves, AUROC) for identifying
people at high risk of incident fatty liver, and the best
accuracy (NPV%) for excluding incident fatty liver at
follow up; using the Youden index method [23].Validation of the performance of established thresholds
and population-specific thresholds in training and
validation data-sets
We established training and validation data-sets to vali-
date the performance of the established and new
population-specific thresholds. To develop training and
validation data-sets, we split the data for each stratum
into training and validation data-sets, using random
sampling methodology to ensure similar distribution of
sex and body mass index (BMI) between both data sub-
sets.
Statistical analysis
The descriptive statistics for continuous variables are
presented using means and standard deviations (SDs) for
normally distributed variables and medians and ranges
for non-normally distributed variables. Categorical
variables were described using frequencies (percentages).
Continuous variables were compared between two
groups using t-test or Mann–Whitney U tests and cate-
gorical variables were analyzed using chi-squared test or
Fisher’s exact test. To identify baseline factors that were
independently associated with incident fatty liver at
follow up, logistic regression analysis was undertaken,
and the odds ratio (OR) and 95% confidence intervals
for incident fatty liver were calculated for continuous
variables. The diagnostic performance of binary criteria
for baseline biochemical and anthropometric tests that
were independently associated with incident fatty liver at
follow up was assessed using ROC curves using both
established cut-points used to define the MetS and cut-
points identified within the study population. All statisti-
cal analyses were performed using SPSS 17.0 (SPSS Inc.,
Chicago, IL, USA) and Stata 11.0 (StataCorp LP, 4905
Lakeway Drive College Station, Texas 77845 USA).
Results
We identified 988 people with prevalent fatty liver and
2589 people who did not have ultrasound evidence of
fatty liver, positive hepatitis B or C serology or excessive
alcohol consumption at baseline examination. Of these
2589 people, 430 developed incident fatty liver, during
the mean follow-up period of average 4.37 years
(1596 days). Table 1 shows a comparison of baseline
characteristics (a) between individuals with and without
fatty liver at baseline and (b) between individuals with
and without incident fatty liver at follow up. Mean
HOMA-IR was higher in the group with fatty liver com-
pared with the group without fatty liver at baseline
(2.69 ± 1.16 v. 1.95 ± 0.69, p≤ 0.0001). There were also a
higher percentage of people with MetS in the group with
fatty liver compared with the group without fatty liver at
baseline (29.7% v. 5.2%, p ≤ 0.0001). A higher proportion
of men (23.4%) than women (9.7%) developed incident
Table 1 Comparison of baseline characteristics (a) between individuals with and without fatty liver at baseline and (b)
between individuals with and without incident fatty liver at follow up
Baseline fatty liver status (a) Follow up fatty liver status (b)
Absent Present (a) Absent Present (b)
p value p value
n 2589 988 2159 430
Age (y) 46.27 ± 8.51 48.08 ± 8.69 <0.0001 46.06 ± 8.57 47.32 ± 8.11 0.005
% Men 1305(50.4%) 800(81.0%) <0.0001 999 (46.3%) 306 (71.2%) <0.0001
BMI (kg/m2) 22.94 ± 2.58 26.10 ± 2.42 <0.0001 22.66 ± 2.53 24.33 ± 2.32 <0.0001
Waist 77.00 ± 8.44 87.52 ± 6.68 <0.0001 75.93 ± 8.25 82.36 ± 7.22 <0.0001
Exercise
None 817(31.5%) 270(27.3%) .002 689 (31.9%) 128 (29.8%) 0.81
≤1time/week 359(13.9%) 183(18.5%) 297 (13.8%) 62 (14.4%)
>1time/week 1413(54.6%) 535(54.1%) 1173 (54.3%) 240 (55.8%)
% Smoker
Never 1821(70.3%) 490(49.6%) <0.0001 1581 (73.2%) 240 (55.8%) <0.0001
Past 293(11.3%) 238(24.1%) 215 (10.0%) 78 (18.1%)
Current 475(18.3%) 260(26.3%) 363 (16.8%) 112 (26.0%)
Alcohol (gm/day) 5.81 ± 7.07 7.68 ± 7.53 <0.0001 5.37 ± 6.82 8.01 ± 7.84 <0.0001
SBP (mmHg) 115.23 ± 13.82 112.39 ± 15.00 <0.0001 114.60± 13.49 118.36 ± 14.97 <0.0001
DBP (mmHg) 74.64 ± 9.89 80.08 ± 10.08 <0.0001 74.06 ± 9.71 77.53 ± 10.25 <0.0001
Triglyceride(mmol/L)Median[IQR] 1.10[0.80,1.51] 1.80[1.33,2.44] <0.0001 1.04[0.77,1.41] 1.38[1.04,1.91] <0.0001
HDL-C (mmol/L) 1.54 ± 0.30 1.40 ± 0.23 <0.0001 1.56 ± 0.31 1.47 ± 0.27 <0.0001
HsCRP (mg/L) 0.82 ± 1.43 1.38 ± 1.75 <0.0001 0.77 ± 1.40 1.03 ± 1.58 <0.0001
Platelets (109/L) 246.14 ± 53.10 235.32 ± 50.57 <0.0001 244.73± 52.63 253.16 ± 54.90 0.003
Albumin (g/L) 45.6 ± 2.4 46.7 ± 2.5 <0.0001 45.4 ± 3.0 45.9 ± .2.3 <0.0001
ALT (U/L) 21.44 ± 15.19 38.39 ± 22.02 <0.0001 20.38 ± 11.67 26.69 ± 25.95 <0.0001
AST (U/L) 22.14 ± 7.11 27.99 ± 10.87 <0.0001 21.87 ± 6.93 23.46 ± 7.83 <0.0001
AST/ALT ratio 1.17 ± 0.36 0.82 ± 0.27 <0.0001 1.19 ± 0.36 1.03 ± 0.33 <0.0001
AST/platelet index 9.46 ± 3.97 11.62 ± 5.81 <0.0001 9.38 ± 3.74 9.86 ± 4.95 0.06
Fasting Glucose(mmol/L) 5.10 ± 0.66 5.55 ± 1.13 <0.0001 5.06 ± 0.56 5.26 ± 1.01 <0.0001
Fasting Insulin (pmol/L) 59.48 ± 18.65 75.39 ± 27.89 <0.0001 58.91 ± 18.18 62.28 ± 20.64 0.002
HOMA-IR 1.95 ± 0.69 2.69 ± 1.16 <0.0001 1.92 ± 0.66 2.10 ± 0.81 <0.0001
MetS, n (%) 135 (5.2%) 293 (29.7%) <0.0001 92 (4.3%) 43 (10.0%) <0.0001
Data are presented as mean (SD), except where indicated.
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HOMA-IR, and a higher prevalence of MetS, in the
people that developed fatty liver during the follow up
period (n = 430) compared with those people who
remained free from developing fatty liver (n = 2159)
(Table 1).
As several individual cardio-metabolic risk factors are
common to insulin resistance, MetS and type 2 diabetes,
we investigated the relationship between individual
cardio-metabolic risk factors at baseline and incident
fatty liver at follow up. The results of analyses in which
all potential baseline cardio-metabolic risk factors were
entered into a logistic regression model with incidentfatty liver as the outcome are shown in Table 2. Age,
sex, hsCRP, blood pressure, HDLc, and smoking did not
have statistically significant independent associations
with incident fatty liver in the fully adjusted model. In
contrast, glucose, waist circumference, triglyceride con-
centration, alanine transaminase (ALT) and platelet
number were all independently associated with incident
fatty liver in this model.
The significant variables identified from regression
analysis (shown in Table 2) were selected for ROC curve
analyses. The performance of these variables in risk pre-
diction modeling for incident fatty liver is summarized
in Table 3. The sensitivity of established thresholds
Table 2 Odds ratios derived from multivariable logistic
regression for the association between age, sex and
cardio-metabolic risk factors at baseline and incident
fatty liver at follow-up
Incident fatty at follow up
OR [95%CIs] p value
Age (per year) 0.990 [0.977, 1.004] 0.176
Male sex 1.103 [0.795, 1.531] 0.557
Glucose (per mmol/l increase) 1.215 [1.042, 1.416] 0.013
Insulin (per pmol/L increase) 1.002 [0.996, 1.008] 0.436
hsCRP (per mg/l increase) 1.286 [0.632, 2.615] 0.488
Triglyceride (per mmol/l increase) 1.378 [1.179, 1.611] <0.0001
HDLc (per mmol/l increase) 0.821 [0.545,1.236] 0.345
ALT (per IU/L increase) 1.009 [1.002, 1.017] 0.016
Platelets (per 1x109/L increase) 1.004 [1.001, 1.006] 0.001
Waist (per cm increase) 1.078 [1.057, 1.099] <0.0001
Smoking (current vs past/never 0.923 [0.696, 1.225] 0.579
DBP (per mmHg increase) 1.003 [0.990, 1.015] 0.656
*or SBP OR [95%CIs] = 1.002[0.993, 1.011], p = 0.65.
Model adjusted for all of above variables.
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identify a group at high risk of incident fatty liver are
shown in Table 3. These thresholds were very good at
identifying people at low risk of incident fatty liver
(negative predictive values (NPVs) for all variables were
between 78.9% and 92.2%).
Since there has been recent debate as to whether there
should be population-specific thresholds for waist cir-
cumference as a key feature of the metabolic syndrome,
we tested the diagnostic performance of population-
specific thresholds that showed the best discrimination
for each of the five factors (waist circumference, glucose,
triglyceride, ALT and platelets), to identify or exclude
incident fatty liver. The results of applying the newly
defined population-specific thresholds of each of these
variables are also shown in Table 3. These data demon-
strated that, for this population, lower thresholds of glu-
cose (5.0 mmol.l−1), waist circumference (78.8 cms
(men) and 73.6 cms (women)), triglyceride (1.1 mmol.l−1),
ALT (24 IU. l−1 (men), and 13 IU. .l−1 (women)) and a
higher platelet count (262x10−9.l−1) than the established
or laboratory based thresholds), resulted in slightly better
diagnostic performance of each test to identify a high risk
group for fatty liver. These population-specific thresholds
also improved performance of each test to exclude fatty
liver (with the exception of ALT in men).
We examined the diagnostic performance of combina-
tions of the variables (waist circumference, and concentra-
tions of glucose, triglyceride and ALT, and platelet count)
to identify high risk of incident fatty liver, using both the
established, and the population-specific measurementthresholds. When all five risk factors (waist circumference,
and concentrations of glucose, triglyceride and ALT, and
platelet count) were combined, for established thresholds,
the area under receiver operator curve (AUROC) value for
incident fatty liver was 0.65 (95%CI 0.61, 0.69), with a
positive predictive value (PPV) of 50.0% (95%CI 15.7,
84.3) and an NPV of 84.0% (95%CI 81.9, 86.0); whereas
for the population-specific thresholds, the AUROC for
incident fatty liver was 0.75 (95%CI 0.72, 0.78), with a
PPV of 40.0% (95%CI 15.7, 84.3) and an NPV of 85.4%
(95%CI 83.3, 87.3). We used the population-specific cri-
teria to calculate the number and proportion of people
who did not have fatty liver at baseline who met all five
thresholds or who met the ALT threshold alone as these
criteria are most likely to be applied in clinical practice to
inform a decision to request a liver ultrasound examina-
tion. The number (%) of people who met all five specific
criteria was 87 (3.4%) whereas 585 people (23%) met the
ALT threshold alone. Consequently, 585 people might be
selected for an ultrasound examination, based upon the
presence of an ALT concentration above the population-
specific threshold for ALT, whereas in contrast only 87
people would be selected for ultrasound investigation, by
using the presence of all five criteria as the essential pre-
requisite.
Next we compared the diagnostic performance of
combining the five factors in the training and the valida-
tion datasets. The performance of both sets of thresh-
olds was very similar in the training and validation data-
sets (Table 4).
Discussion
Our study is the first to combine identification of risk
factors with the subsequent testing of these factors in
risk prediction modeling for incident fatty liver at follow
up. Whilst others have examined relationships between
risk scores (or cardio-metabolic risk factors) and prevalent
fatty liver in cross sectional studies [13-17], we have exam-
ined the AUROC, NPV and PPV of risk factors identified
at baseline, to predict incident cases of fatty liver at aver-
age follow up of 4.4 years. We show that combination of
thresholds of five easily measured risk factors (waist
circumference, glucose, ALT, platelets and triglyceride)
allows identification of the small proportion of people at
high risk of incident fatty liver who could then be selected
for hepatic imaging tests. Such an approach would focus
the use of relatively expensive non-invasive diagnostic
imaging tests, such as ultrasound, and would be likely to
increase the specificity of this imaging test to diagnose
fatty liver, and lead to more cost effective use of limited
resources. Additionally, our data suggest that in this
cohort the population-specific thresholds are possibly
better at diagnosing, or identifying, people at high risk of
fatty liver (than the established thresholds). In contrast,
Table 3 Comparison of the performance of key variables at baseline to identify incident fatty liver at follow up, using
established and newly optimized thresholds of each variable*
Established thresholds
Test Cut point AUROC
(95%CI)
Sensitivity (%) (95%CI) Specificity (%)
(95%CI)
PPV (%) (95%CI) NPV (%) (95%CI)
Glucose 5.6 (mmol/l) 0.56 24.9% 86.6% 26.4% 85.7%
(0.53–0.59) (19.2%–31.3%) (84.5%–88.6%) (20.4%–33.1%) (83.5%–87.7%)
Waist 90 (cms) men 18.4% 88.5% 31.8% 78.9%
0.56 (12.5%–25.6%) (85.4%–91.2%) (22.1%–42.8%) (75.3%–82.2%)
80 (cms) women (0.53–0.58) 29% 90.5% 24.7% 92.2%
(18.2%–41.9%) (87.8%–92.8%) (15.3%–36.1%) (89.7%–94.3%)
Triglyceride 1.7 (mmol/l) 0.60 35.9% 85.1% 31.6% 87.3%
(0.57–0.64) (29.4%–42.8%) (82.8%–87.1%) (25.8%–38.0%) (85.2%–89.3%)
ALT 30 (IU/l) 32.7% 75.7% 28.1% 79.5%
(men) 0.52 (25.2%–40.9%) (71.7%–79.4%) (21.5%–35.4%) (75.6%–83%)
19 (IU/l) (0.49–0.56) 32.3% 69.4% 10.2% 90.5%
(women) (20.9%–45.3%) (65.4%–73.1%) (6.31%–15.2%) (87.4%–93.1%)
Platelets 158 (x109/l) 0.51 97.6% 3.32% 16.3% 87.8%
(0.49–0.52) (94.5%–99.2%) (2.34%–4.57%) (14.3%–18.5%) (73.8%–95.9%)
Population–specific thresholds
Test Cut point AUROC
(95%CI)
Sensitivity (%) (95%CI) Specificity (%)
(95%CI)
PPV (%) (95%CI) NPV (%) (95%CI)
Glucose 5.0 mmol/l 0.58 70.8% 45.4% 20.0% 89.0%
(0.55–0.62) (64.1%–76.9%) (42.4%–48.4%) (17.2%–23.1%) (86.1%–91.5%)
Waist 78.8 cms (men) 87.7% 35.2% 28.2% 90.8%
0.68 (81.0%–92.7%) (30.9%–39.6%) (24.1%–32.5%) (85.8%–94.4%)
73.5 cms (women (0.65–0.71) 72.4% 67.9% 19.1% 95.6%
(59.1%–83.3%) (63.8%–71.8%) (14.3%–24.8%) (93.2%–97.4%)
Triglyceride 1.1 mmol/l 0.64 76.1% 52.2% 23.5% 91.9%
(0.61–0.67) (69.7%–81.7%) (49.2%–55.2%) (20.3%–26.9%) (89.4%–93.9%)
ALT 24 (IU/l) 55.8% 60.7% 29.2% 82.5%
(men) 0.54 (47.4%–64%) (56.3%–65.0%) (23.9%–34.9%) (78.3%–86.2%)
13 (IU/l) (0.51–0.57) 85.5% 27.5% 11.2% 94.6%
(women) (74.2%–93.1%) (23.9%–31.3%) (8.53%–14.4%) (90.1%–97.5%)
Platelets 262 (x109/l) 0.56 47.4% 64.9% 20.7% 86.5%
(0.52–0.60) (40.4%–54.4%) (62.0%–67.8%) (17.1%–24.6%) (83.9%–88.8%)
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people at low risk of, or excluding, fatty liver.
Interestingly, the factors that we have identified as
being associated with increased risk of developing fatty
liver are also strongly associated with risk of type 2 dia-
betes either directly, (glucose, triglyceride, ALT and waist
circumference) [24], or as a consequence of their asso-
ciation with the metabolic syndrome (platelet count)
[25]. This finding clearly emphasizes the importance of
shared risk factors for both cardio-metabolic and fatty
liver diseases in a general middle-aged population and
strongly suggests a common etio-pathogenesis for type 2diabetes and NAFLD. Although age is a strong risk
factor for type 2 diabetes, age was not an independent
risk factor for NAFLD in this occupational cohort, per-
haps because the age range was fairly narrow and
because the effect of age is at least partly mediated
through other factors included in our model.
The unexpected finding that platelet count was asso-
ciated with increased risk of fatty liver may be explained
by the fact that platelets are a potential mediator of
inflammation [26,27] and some of the individuals with
incident fatty liver at follow up may have developed a
more severe form of NAFLD with inflammation and
Table 4 Performance (AUROC and 95%CIs) of combination of baseline tests for identifying incident fatty liver in
training data-set and validation data-set
training data-set validation data-set
New thresholds
(A) glucose, waist, triglyceride, ALT, platelets 0.75 0.71
(95% CI : 0.72–0.78) (95% CI : 0.67–0.74)
Established thresholds
(B) glucose, waist, triglyceride, ALT, platelets 0.65 0.68
(95% CI : 0.61–0.69) (95% CI : 0.65–0.72)
A) Combining thresholds of glucose, waist, triglyceride, ALT and platelets using new optimized measurement thresholds, and
(B) Combining thresholds of glucose, waist, triglyceride, ALT and platelets using established measurement thresholds.
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research is needed to explore further the relationship
between platelet activation and development of NAFLD.
Recent findings that both platelet-derived serotonin and
platelet release of the key profibrogenic mediators CXC
Chemokine Ligand 4 and transforming growth factor-β
(TGF-β), all support the notion that platelet activation
may be involved in NAFLD progression [27,28].
The diagnostic performance of ultrasound, computed
tomography (CT), T1-weighted dual-echo magnetic
resonance (MR) imaging, and point-resolved proton
(hydrogen 1[(1)H]) MR spectroscopy in the assessment
of hepatic steatosis has previously been compared. MR
spectroscopic measurements of hepatic fat and ultra-
sound measurement of liver fat both correlate well with
histopathologic steatosis assessment [29]. Furthermore,
compared with histopathologic steatosis assessment (as
the gold standard), the sensitivity of ultrasound and MR
spectroscopy, was 65% and 91%, respectively, whereas
the specificity was 77% and 87% respectively. Thus, in
establishing an initial diagnosis of NAFLD it is accepted
that ultrasound has an acceptable balance of sensitivity
and specificity to detect liver fat, particularly where there
is >30% liver tissue fat infiltration [30]. Although ultraso-
nography is a reasonably accurate technique for detecting
modest amounts of liver fat (>30% liver fat infiltration),
ultrasound has poor sensitivity to detect minor amounts
of fatty infiltration [30] and it would be important to
test the ability of our five simple cardio-metabolic risk
factors to predict lesser amounts of liver fat. However, it
was not possible for us to undertake this analysis in our
prospective study design as an MRS investigation at
baseline and at follow up would have been required in
2589 people.
There are several strengths to our study. There is a
considerable body of published research that has investi-
gated cross sectional associations of risk factors with
liver fat. To our knowledge, no previous studies have
described the etiological factors associated with incident
NAFLD in a longitudinal study, and then tested the uti-
lity of these factors in risk prediction modeling in ageneral population. Other studies have used more sensi-
tive tests for detecting liver fat, such as the MRS-based
study that focused on developing a risk score (for liver
fat) [18]; but these investigators employed cross sectional
analyses, in a population that was not solely recruited
from a general population. Moreover the investigators
used measurements of insulin concentrations that are
also not readily available to the primary care physician.
Recently, using abdominal ultrasonography, Tsuneto
et al. [31] examined 1635 Nagasaki atomic bomb survi-
vors (606 men) biennially without fatty liver at baseline,
for a mean follow-up of 11.6+/−4.6 years. In all, 323
(124 men) incident fatty liver cases were diagnosed. The
incidence of fatty liver was 19.9/1000 person-years (22.3
for men, 18.6 for women) and peaked in the sixth
decade of life. In multivariate analysis, obesity (RR, 2.55;
P < 0.001), hypertriglyceridemia (RR, 1.92; P < 0.001) and
hypertension (RR, 1.31; P = 0.046) were independently
associated with incident fatty liver. Our results are
largely in agreement with these findings, and our work
on risk prediction extends this work. Tsuneto et al.
showed a borderline significant independent association
between blood pressure and fatty liver, a finding that
was not confirmed in our study. Interestingly, despite
the younger age distribution, the incidence rate for fatty
liver was higher in our study (at 34.7/1000 person years).
Our study has some limitations. We have used routine
clinical data so that although ultrasonography was
undertaken by experienced clinical radiologists, a formal
assessment of inter-observer variability was not possible.
As the incidence rate for NAFLD is probably highest in
the sixth decade [31], and because our study population
included a relatively narrow age range with a preponder-
ance of men, our estimates of fatty liver incidence can-
not be extrapolated to the whole population. We do not
have data describing behaviour during the follow up
period, and therefore we are unable to comment as to
whether there was any change between baseline and fol-
low up measurements that may have affected risk of
fatty liver. As ultrasound does not detect liver fat ≤30%
fat infiltration, it is possible that some people had small
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detectable. We have studied a single population largely
comprising one ethnic group and consequently, our
results cannot be extrapolated to other ethnic groups.
However, our cohort comprises an ethnic group who are
typical of a large percentage of the population of North-
east Asia that represents as many as 1.5 billion people.
We were unable to exclude subjects taking drugs known
to be associated with increased risk of fatty liver as these
data were not available, although in this population-
based cohort, this is likely to be a very small percentage
of the total cohort.
Conclusions
We have identified simple baseline etiological factors
(waist circumference, glucose, triglyceride and ALT con-
centrations, and platelet number) that are associated
with incident fatty liver over a follow up of an average of
4.4 years. Importantly, we have shown that the diagnos-
tic performance of either the population-specific or the
established thresholds used in the definition of the MetS
is such that either could be used in clinical practice to
focus limited resources and identify a high risk subgroup
for fatty liver. We suggest that this selected sub-group
should receive a liver ultrasound and may derive particu-
lar benefit from lifestyle change and assessment and
management of diabetes risk as well as the hepatic dis-
ease risk. We suggest that thresholds of these five factors
combined, could be used as a screening tool to select
people who are particularly likely to, either already have,
or to develop fatty liver. Such an approach would
improve the use and specificity of ultrasound imaging in
a more targeted approach to the diagnosis of fatty liver.
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